A robust gene expression signature for NASH in liver expression data

Area of Science:

• Hepatology and Molecular Biology
• Genomics and Bioinformatics
• Diagnostic Biomarker Development

Background:

• Non-Alcoholic Fatty Liver Disease (NAFLD) affects up to 30% globally, with 25% progressing to Non-Alcoholic SteatoHepatitis (NASH), a severe inflammatory form.
• Current diagnostic methods lack generalizability for distinguishing NASH from NAFLD in diverse patient populations.
• There is an urgent clinical need for reliable diagnostic tools for NASH.

Purpose of the Study:

• To identify a gene expression signature for accurate diagnosis of NASH.
• To develop a robust diagnostic method applicable across diverse patient cohorts.
• To leverage transcriptome data for advancing NASH diagnostics.

Main Methods:

• Comprehensive multicohort analysis of 812 transcriptome datasets from Healthy Controls (HC), NAFLD, and NASH patients across 7 countries.
• Utilized 7 datasets for discovery and 5 independent datasets for validation.
• Identified differentially expressed genes and downselected to a 19-mRNA signature using advanced statistical methodology.

Main Results:

• Identified 130 significantly differentially expressed genes in NASH versus HC/NAFLD.
• Developed a parsimonious 19-mRNA signature with high diagnostic performance: mean AUROC of 0.98 in discovery and 0.79 in validation.
• The signature reflects a true biological signal, not driven by specific patient subgroups.

Conclusions:

• Gene expression profiling combined with advanced statistical analysis can form the basis for developing accurate NASH diagnostic tests.
• The identified 19-mRNA signature shows significant potential for clinical application in distinguishing NASH from NAFLD.
• This approach addresses a critical unmet need for reliable NASH diagnostics in the global population.